Breast Cancer Clinical Trial

EHR-embedded OCDT in Breast or GI Cancer

Summary

This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study is to help researchers better understand gaps in assessing oral chemotherapy patient toxicity at home, adherence to treatment and integrate toxicity/adherence reporting.

View Full Description

Full Description

For patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.

Participants will complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice

Participants between clinic visits, will be asked to complete the oral weekly survey at home via the mobile or web based patient portal. The survey can be completed on a computer, tablet or smartphone at home or on a tablet at the time of scheduled visit.

The first 100 participants to complete the survey will receive a passive care team alert for responses (per DFHCC policy)
The second 100 participants to complete the survey will receive an active care team alert for responses.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adult age 18 or older
Male or Female
Scheduled visit at DF/HCC within the BOC or GCC
Diagnosis of advanced breast cancer or gastrointestinal cancer
Prescribed any OCDT within prior 5 days of screening
English as the primary language (as documented in the EHR, written or spoken, and patient interpreter needed flag = no)
Mobile number listed in EHR to allow participation in ePP portion of the study
Women of any pregnancy status
Patients diagnosed with an advanced cancer will be eligible to participate in the study until discontinuation of OCDT or death, whichever occurs first

Exclusion Criteria

Adults unable to provide verbal consent
Pediatric patients
Patients without access to a electronic device (including tablet, computer, aptop or smartphone)

Study is for people with:

Breast Cancer

Estimated Enrollment:

100

Study ID:

NCT03858712

Recruitment Status:

Completed

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Dana Farber Cancer Institute
Boston Massachusetts, 02115, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

100

Study ID:

NCT03858712

Recruitment Status:

Completed

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider